Showing results 3 to 8 of 8
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
2015 | |||
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Journal:New England Journal of Medicine | 2015 | ||
Sofosbuvir plus ribavirin for 12 16 or 24 weeks results in sustained virologic response over 97% in genotype 1 and 6 HCV infection in Hong Kong Proceeding/Conference:Hepatology International | 2015 | ||
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong Journal:Alimentary Pharmacology & Therapeutics | 2016 | ||
Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study Proceeding/Conference:Hepatology International | 2016 | ||
2017 |